
































More than twenty-five million individuals may suffer 
from Alzheimer’s disease, pre-senile dementia, and 
other disorders of cognitive loss throughout the world 
[1, 2].  β-amyloid (Aβ) deposition in the brain is 
considered to be a significant component of 
Alzheimer’s disease that leads to progressive neuro-
degeneration.  Aβ toxicity can involve multiple cell 
types including neurons [3-6], vascular cells [2, 7, 8], 
and inflammatory microglial cells [7, 9].  In regard to 
microglia, these inflammatory cells can form a 
protective network for the brain to control neurotrophic 
factors [10], limit oxidative stress [11, 12], and foster 
neuronal regeneration [13].  Microglia also may limit 
the deposition and toxicity of Aβ and promote neuronal 
survival [4, 9, 14-16]. 
 
In light of the significance microglia may hold as 
therapeutic targets directed against Alzheimer’s disease, 
it becomes vital to understand the cellular pathways that 
maintain microglia survival during Aβ toxicity.  One 
therapeutic  agent  that  may  provide protection  against  
 
 






























both Alzheimer’s disease and microglial injury is the 
cytokine and growth factor erythropoietin (EPO) [3, 17-
19].  EPO has broad protective effects in the heart, the 
vasculature, and the nervous system [20-28].  EPO also 
is involved in immune system modulation [29-31] and 
controls the activation and proliferation of microglia 
[24, 32-35].  Recent studies have suggested that the 
wingless cysteine-rich glycosylated protein Wnt1 [36-
38] may limit the production and toxicity of Aβ [39, 
40].  Wnt1 and the wingless pathway offer cellular 
protection through non-neuronal cells including 
microglia [4, 41-43] and mediate EPO cytoprotection in 
experimental models of diabetes mellitus and hypoxia 
[20, 44, 45].  Interestingly, Wnt1 does not entirely rely 
upon traditional canonical and non-canonical pathways 
[46, 47] and can function through the phosphoinositide 
3-kinase (PI 3-K) and Akt1 pathways in the apoptotic 
cascade [4, 20, 41, 43, 48].  
  
Given that Wnt1 can prevent apoptosis through PI 3-K 
mediated pathways [49-51], we investigated whether 
EPO and Wnt1 employed the PI 3-K/Akt1/mammalian 
target of rapamycin (mTOR) pathways to protect 
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central component for EPO to promote microglial 
integrity and prevent the loss of these cells during early 
and late apoptotic injury with Aβ exposure.  Wnt1 
depends upon PI 3-K, Akt1, mTOR, and p70S6K to 
maintain microglial viability during Aβ exposure.   
Wnt1 regulates the apoptotic cascade by maintaining 
mitochondrial membrane potential, phosphorylating and 
fostering the translocation of Bad from the 
mitochondria to the cytosol, reducing the Bad/Bcl-xL 
complex, increasing the Bcl-xL/Bax complex, and 





EPO protects microglia against beta-amyloid 1-42 
(Aβ) exposure through Wnt1 
 
Aβ was applied to microglia in a series of concentration 
(1, 5, 10, and 20 μM) and microglial cell survival was 
assessed 24 hours later by the trypan blue dye exclusion 
method.  As shown in Figure 1A, Aβ significantly 
decreased cell survival to 73 ± 3%, 41 ± 3%, and 19 ± 
4% at the concentrations of 5 μM, 10 μM, and 20 μM 
respectively 24 hours following Aβ administration when 
compared to untreated control cells with a survival of 
92 ± 6%.  The Aβ concentration of 1 μM was not 
significantly toxic with a cell survival of 84 ± 7%.   
Since the Aβ concentration of 10 μM resulted in a 
survival of approximately 40% (60% microglial cell 
loss), this concentration of Aβ was employed for the 
subsequent experimental paradigms. 
 
We investigated the ability of EPO to prevent microglial 
cell injury following Aβ exposure.  A concentration of 
EPO 10 ng/ml was used since this concentration has 
previously been shown to provide significant 
cytoprotection without toxicity in several experimental 
systems including those involving Aβ [20, 21].  EPO 
(10 ng/ml) was applied to microglia at 24, 12, 6, and 1 
hour prior to the administration of Aβ and cell survival 
was determined 24 hours later.  As shown in Figure 1B, 
cell survival was increased from 36 ± 6 %  i n  c e l l s  
exposed to only Aβ alone to 63 ± 7% (1 hour), 58 ± 6% 
(6 hours), 55 ± 4% (12 hours), and 47 ± 7% (24 hours) 
respectively, illustrating that administration of EPO 
closest to the point of Aβ exposure yielded the greatest 
degree of cytoprotection for microglia.  We therefore 
utilized a 1 hour application of EPO prior to Aβ 
exposure for subsequent studies. 
 
In Figures 1C and 1D, trypan blue dye exclusion 
staining was used to assess microglial cell injury.  Early 
apoptotic injury was assessed by membrane 
phosphatidylserine (PS) exposure (annexin V staining) 
and late apoptotic genomic DNA fragmentation was 
assessed by TUNEL 24 hours following Aβ exposure.  
As shown in Figures 1C and 1D, representative images 
and quantitative results demonstrate that Aβ led to a 
significant increase in trypan blue staining, DNA 
fragmentation, and membrane PS exposure in microglia 
at 24 hours after Aβ exposure when compared to 
untreated control cultures.  Yet, treatment with EPO (10 
ng/ml) 1 hour prior to Aβ exposure significantly 
decreased trypan blue dye uptake, DNA fragmentation, 
and membrane PS exposure in microglia 24 hours 
following Aβ administration (Figures 1C and 1D). 
 
We examined the ability of EPO to alter the expression 
of Wnt1 in microglia during Aβ exposure.  Western blot 
assay was performed for the endogenous cellular 
expression of Wnt1 at 6 hours following Aβ 
administration.  A representative Western blot 
demonstrates that Wnt1 expression was decreased 
within 6 hours following Aβ exposure (Figures 1E and 
1F).  Application of EPO (10 ng/ml) in microglia 
significantly maintained the expression of Wnt1 at 6 
hours after Aβ exposure (Figures 1E and 1F), 
illustrating that EPO can maintain the expression of 
Wnt1 during Aβ exposure. 
 
As shown in Figure 1E and 1F, transfection with Wnt1 
siRNA in microglia resulted in the significant reduction 
of Wnt1 expression as revealed by Western blot 
analysis at 6 hours following Aβ exposure.  As a 
control, non-specific scrambled siRNA did not alter 
Wnt1 protein expression in untreated control microglia 
or in microglia exposed to Aβ alone, demonstrating that 
Wnt1 siRNA was specific to block protein expression of 
Wnt1.  Application of EPO (10 ng/ml) or of Wnt1 (100 
ng/ml) 1 hour prior to Aβ exposure significantly 
maintained the expression of Wnt1 similar to control 
cultures.  However, gene reduction of Wnt1 with siRNA 
in the presence of EPO (10 ng/ml) prevented EPO from 
maintaining the expression of Wnt1 during Aβ exposure 
(Figures 1E and 1F).  
 
We investigated whether gene reduction of Wnt1 could 
impact protection by EPO.  As shown in Figure 1G, 
representative images demonstrate that Aβ exposure 
leads to a significant increase in trypan blue staining, 
genomic DNA fragmentation, and PS membrane 
externalization in microglia 24 hours later.  EPO (10 
ng/ml) or Wnt1 (100 ng/ml) prevented cell injury, DNA 
fragmentation, and membrane PS exposure (Figures 1G 
and 1H).  In contrast, gene reduction of Wnt1 with 
siRNA  increased  cell  injury  when compared with  Aβ  
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necessary for microglial protection during Aβ exposure 
(Figures 1G and 1H).  In addition, gene reduction of 
Wnt1 with siRNA during EPO application significantly 
blocked protection by EPO, also illustrating that Wnt1 
is required for EPO cytoprotection in microglia during 
Aβ exposure (Figures 1G and 1H). Interestingly 
combined treatment with EPO (10 ng/ml) and Wnt1 
(100 ng/ml) provides similar protection when compared 
with EPO alone treatment and slightly improved 
protection when compared with Wnt1 treatment alone, 
suggesting that EPO relies on Wnt1 for cellular 
protection against Aβ exposure, but also may utilize 
other signal transduction pathways (Figure 1H). 
 
EPO maintains the activity of Akt1 through Wnt1 
during Aβ exposure 
 
Western blot assay for the expression of phosphorylated 
Akt1 (p-Akt1) (activated form of Akt1) was performed 
following Aβ exposure.  As shown in Figure 2A, the 
expression of p-Akt1 was mildly increased at 6, 12, and 
24 hours following Aβ exposure.  Application of EPO 
(10 ng/ml) 1 hour prior to Aβ significantly increased the 
expression of p-Akt1 6 hours following Aβ and 
maintained the increased expression of p-Akt1 over a 24 
hour following Aβ administration (Figure 2A).  In a 
similar manner, we assessed Akt1 activity through a 
GSK-3β fusion protein (Figure 2B).  EPO 
administration 1 hour prior to Aβ also significantly 
increased and maintained the activity of Akt1 
determined by the expression of p-GSK-α/β when 
compared to microglia exposed to Aβ only (Figure 2B). 
 
We assessed the ability of EPO to maintain activation of 
Akt1 during gene reduction of Wnt1. As shown in 
Figure 2B, representative images demonstrate that EPO 
(10 ng/ml) or Wnt1 (100 ng/ml) significantly increase 
the expression of p-Akt1 at 6 hours following Aβ 
exposure.  However, gene reduction of Wnt1 with 
siRNA significantly during EPO application 
significantly reduced the expression of p-Akt1 at 6 
hours following Aβ exposure in microglia (Figure 2C), 
illustrating that Wnt1 is a necessary component for EPO 









































































Figure  2.  EPO  maintains  Akt1  activation  through  Wnt1
during Aβ exposure.  (A)  Microglial protein extracts (50 μg/ 




significantly  increased  the  expression  of  p‐Akt1  over  a  24  hour
period following Aβ exposure (*P < 0.01 vs. Control; †P< 0.01 vs.
Aβ  of  corresponding  time  point).  In  all  cases,  each  data  point
represents the mean and SEM from 3 experiments.   
   























































































































determined  at 6 hours  following  Aβ  exposure.  EPO  (10  ng/ml)  or  Wnt1  (100  ng/ml)  applied  1 hour  prior  to  Aβ  exposure
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3-K/Akt1 pathway to protect microglia during A β 
exposure 
 
The mammalian target of rapamycin (mTOR) and 
p70S6K are downstream targets of Akt1 [52, 53].  Since 
they are phosphorylated and activated through Akt1, we 
investigated whether EPO could alter mTOR and 
p70S6K activity during Aβ exposure.  Western blot 
assay for phosphorylated mTOR (p-mTOR) (activated 
form of Akt1) and phosphorylated p70S6K (p-p70S6K) 
(activated form of p70S6K), a down stream target of 
mTOR, were performed following Aβ exposure.  As 
shown in Figure 3A, the expression of p-mTOR and p-
p70S6K was increased 6, 12, and 24 hours following 
Aβ exposure alone.  In contrast, EPO (10 ng/ml) with a 
1 hour pretreatment significantly increased and 
maintained the expression of p-mTOR and p-p70S6K at 
6, 12, and 24 hours following Aβ exposure.  As shown 
in Figure 3B, gene reduction of Wnt1  with siRNA 
during EPO (10 ng/ml) application resulted in 
significantly decreased expression of p-mTOR and p-
p70S6K 6 hours following Aβ exposure, suggesting that 
EPO increases mTOR and p70S6K activity through 
Wnt1.  In Figures 3C and 3D, application of the 
phosphoinositide 3-kinase (PI 3-K) inhibitor LY294002 
(10 μM) during treatment with either EPO (10 ng/ml) or 
Wnt1 (100 ng/ml) prevented EPO or Wnt1 from 
phosphorylating mTOR and p70S6K, illustrating that 
the PI 3-K and Akt1 pathways are necessary for EPO or 
Wnt1 to phosphorylate mTOR and p70S6K.  The 
inhibitor LY294002 (10 μM) reversibly competes for 
ATP binding with PI 3-K [54].  In addition, combined 
application of EPO (10 ng/ml) and Wnt1 (100 ng/ml) 
phosphorylated mTOR and p70S6K to the same level as 
either agent applied independently and phosphorylation 
of mTOR and p70S6K was lost during application of 
LY294002 (10 μM), suggesting that EPO and Wnt1 use 
a common pathway to activate mTOR and p70S6K 
involving PI 3-K and Akt1 (Figures 3C and 3D). 
 
We assessed whether EPO and Wnt1 required the 
mTOR pathway to prevent microglial cell injury.   
Microglial cell injury was determined by the trypan blue 
dye exclusion method 24 hours following Aβ exposure.  
As shown in Figures 3E and 3F, Aβ exposure results in 
a significant increase in trypan blue staining in 
microglia.  EPO (10 ng/ml) or Wnt1 (100 ng/ml) 
applied 1 hour prior to Aβ exposure significantly 
reduced trypan blue staining in microglia (Figures 3E 
and 3F).  Yet, administration of the mTOR inhibitor 
rapamycin (RAPA, 50 nM) or the specific mTOR 
inhibitor Ku 0063794 (KU, 100 nM) [55] with EPO (10 
ng/ml), Wnt1 (100 ng/ml), the combination of EPO (10 
ng/ml) and Wnt1 (100 ng/ml) blocked the ability of 
EPO and Wnt1 to prevent microglial cell injury during 
Aβ exposure, suggesting the mTOR pathway was 
necessary for EPO and Wnt1 microglial protection 
(Figures 3E and 3F).   
 
EPO phosphorylates Bad and fosters mitochondrial 
organelle release of Bad through Wnt1 and mTOR 
Given that EPO utilizes Wnt1 and mTOR for microglial 
cytoprotection, we investigated the ability of EPO to 
phosphorylate Bad, an important modulator of cell 
injury and a downstream target of Akt1 at the 
phosphorylation site of Bad (Ser
136) [43, 56].  As shown 
in Figure 4A, phosphorylation of Bad (p-Bad) was 
decreased at 6 hours and 12 hours following exposure to 
Aβ alone.  In contrast, EPO (10 ng/ml) applied 1 hour 
prior to Aβ exposure significantly increased the 
expression of p-Bad at 6 hours, 12 hours, and 24 hours 
following Aβ exposure.  Yet, the ability of EPO (10 
ng/ml) to phosphorylate Bad 6 hours following Aβ 
exposure was lost with the gene reduction of Wnt1, 
suggesting that EPO requires Wnt1 to phosphorylate 
Bad and lead to its activation.  Use of non-specific 
scrambled siRNA did not alter the phosphorylation of 
Bad during Aβ exposure.  In addition, microglia treated 
with Wnt1 siRNA were also unable to phosphorylate 
Bad during Aβ exposure (Figure 4B).  In Figure 4C, 
administration of the mTOR inhibitor rapamycin (50 
nM) prevented both EPO (10 ng/ml) and Wnt1 (100 
ng/ml) from phosphorylating Bad 6 hours following Aβ 
exposure, illustrating that EPO as well as Wnt1 required 
mTOR to phosphorylate Bad during Aβ exposure.  In 
addition to maintaining the phosphorylation of Bad, 
EPO and Wnt1 also foster the translocation of Bad from 
mitochondria to the cytosol.  In Figure 4D, EPO (10 
ng/ml) and Wnt1 (100 ng/ml) independently promote 
the release of Bad into the cytosol from microglial 
mitochondria 6 hours after Aβ exposure.  Loss of Wnt1 
during gene reduction of Wnt1 abrogates the ability of 
EPO to lead to the release of Bad from mitochondria to 
the cytosol.  Use of non-specific scrambled siRNA did 
not alter the phosphorylation of Bad during Aβ 
exposure (Figure 4D). 
 
EPO and Wnt1 release Bad from Bcl-xL and increase 
the binding of Bcl-xL to Bax 
 
We subsequently examined the ability of EPO and 
Wnt1 to alter Bad and Bcl-xL binding as well as the 
association between Bcl-xL and Bax.  EPO (10 ng/ml) 
or Wnt1 (100 ng/ml) were applied 1 hour prior to Aβ 
exposure and microglial cell extracts at 6 hours 
following Aβ were immunoprecipitated using anti-bodies 
to  Bad,   Bcl-xL,  and  Bax.   As   shown in  Figure  4E,  
   






















































































































was  performed  in  microglia  with  transfection  of  Wnt1  siRNA  prior  to  Aβ  (10  μM)  administration.  Protein  extracts  were 












Bad,  controls  mitochondrial  trafficking  of
Bad,  and  modulates  Bad,  Bcl‐xL,  and  Bax
binding.    (A)  Microglial  protein  extracts  (50






hour  pretreatment  significantly  increased  the
expression of p‐Bad 6 hours following Aβ exposure
(*P  <0.01  vs.  Control;  †P<0.01  vs.  Aβ  of
corresponding exposure time).  In all cases, each
data point represents the mean and SEM from 3
experiments.  (B)  Gene  reduction  of  Wnt1  was
performed with transfection of Wnt1 siRNA prior
to  Aβ  (10  μM)  administration  in  microglia.  The
expression  of  p‐Bad  was  determined  at  6  hours
following Aβ exposure.  EPO (10 ng/ml) or Wnt1
(100  ng/ml)  with  1  hour  pretreatments
significantly  increased  the  expression  of  p‐Bad  6
hours  following  Aβ  exposure.  Yet,  Wnt1  siRNA
transfection prior to Aβ exposure prevented EPO






hour  pretreatments  significantly  increased  the
expression of p‐Bad 6 hours following Aβ (10 μM)
exposure.  Application  of  the  mTOR  inhibitor
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immunoprecipitation demonstrates that Aβ exposure 
alone as well as with non-specific scrambled siRNA 
resulted in a significant increase in the expression of the 
Bad/Bcl-xL complex when compared to untreated 
controls.  In contrast, EPO (10 ng/ml) and Wnt1 (100 
ng/ml) significantly reduced the expression of the 
Bad/Bcl-xL complex when compared with untreated 
control cultures (Figure 4E).  Furthermore, gene 
reduction of Wnt1 during EPO treatment with Aβ 
results in significant expression of the Bad/Bcl-xL 
complex, suggesting that Wnt1 is vital to allow Bad to 
release Bcl-xL  to block apoptosis.  In Figure 4F, Aβ 
exposure alone as well as the non-specific scrambled 
siRNA result in a significant decrease in the expression 
of the Bcl-xL/Bax complex when compared to untreated 
microglial controls.  Yet, EPO (10 ng/ml) and Wnt1 
(100 ng/ml) significantly increase the expression of the 
Bcl-xL/Bax complex during Aβ exposure.  The ability 
of EPO to block the apoptotic cascade by maintaining 
the Bcl-xL/Bax complex [57] is lost during Wnt1 gene 


































tering the Bcl-xL/Bax complex during Aβ exposure. 
 
EPO prevents mitochondrial membrane 
depolarization during Aβ exposure through Wnt1 
 
In Figure 5A, Aβ exposure yielded a significant 
decrease in the microglial mitochondrial red/green 
fluorescence intensity ratio at 6 hours following Aβ 
exposure when compared to untreated control 
microglia, suggesting that Aβ exposure results in 
mitochondrial membrane depolarization.  EPO (10 
ng/ml) or Wnt1 (100 ng/ml) administration 1 hour prior 
to Aβ exposure significantly increased the red/green 
fluorescence intensity of the mitochondria, illustrating 
that EPO or Wnt1 can maintain mitochondrial 
permeability transition pore membrane potential during 
Aβ exposure.  In contrast, EPO (10 ng/ml) could not 
maintain mitochondrial membrane potential during gene 
reduction of Wnt1, illustrating that Wnt1 modulates 
mitochondrial membrane potential for EPO (Figure 
5A).  Non-specific scrambled siRNA did not alter 






































































EPO and Wnt1 require Bcl-xL to prevent caspase 1 
and caspase 3 activation during Aβ exposure 
 
We subsequently examined the ability of EPO and 
Wnt1 to control caspase 1 and caspase 3 activities.  In 
Figures 5B and 5C, the expression of cleaved (active) 
caspase 1 and caspase 3 on western analysis were 
significantly increased at 6 hours following Aβ 
exposure.  EPO (10 ng/ml) or Wnt1 (100 ng/ml) 
application significantly blocked caspase 1 and caspase 
3 activity during Aβ exposure (Figures 5B and 5C).  In 
contrast, transfection with Wnt1 siRNA during EPO 
treatment resulted in a significant elevation in caspase 1 
and caspase 3 activities, suggesting that Wnt1 in 
microglial mediates the ability of EPO to control 
caspase activity during Aβ exposure (Figure 5B).  In 
addition, transfection with Bcl-xL siRNA during EPO 
(10 ng/ml) or Wnt1 (100 ng/ml) treatment blocked the 
ability of EPO or Wnt1 to control caspase 1 or caspase 




































ability of EPO and Wnt1 to regulate caspase 1 and 
caspase 3 activity in microglia during Aβ exposure 
(Figure 5C).  Non-specific scrambled siRNA did not 
alter the ability of EPO or Wnt1 to suppress caspase 1 
or caspase 3 activity, supporting the specificity of Bcl-
xL through EPO or Wnt1 to regulate these pathways 
(Figure 5C). 
 
EPO and Wnt1 block early and late apoptotic 
microglial degeneration through Bcl-xL during Aβ 
exposure 
 
In Figures 5D and 5E, microglial cell injury was 
assessed with trypan blue staining.  Early apoptotic 
injury was assessed by membrane PS exposure (annexin 
V staining) and late apoptotic genomic DNA 
fragmentation was assessed by TUNEL 24 hours 
following Aβ exposure.  Treatment with EPO (10 
ng/ml) or Wnt1 (100 ng/ml) blocked cell injury, early 
apoptotic injury with membrane PS exposure, and late 
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However, gene reduction of Bcl-xL with siRNA during 
EPO or Wnt1 application significantly prevented 
protection by EPO or Wnt1, illustrating that Bcl-xL is 
necessary for EPO and Wnt1 prevention of microglial 
degeneration during Aβ exposure (Figures 5D and 5E).  
Combined treatment with EPO (10 ng/ml) and Wnt1 (100 
ng/ml) also resulted in similar protection when compared 
with EPO or Wnt1 alone but combined protection was 
lost during gene reduction of Bcl-xL with siRNA, 
suggesting that EPO and Wnt1 rely upon Bcl-xL in 
microglia to foster protection against Aβ (Figures 5D and 
5E).  Non-specific scrambled siRNA did not alter micro-




Therapeutic strategies that target the accumulation and 
toxicity of Aβ in the brain during Alzheimer’s disease 
may offer significant promise for the treatment of this 
neurodegenerative disorder [2, 5, 58].  In particular, 
focus upon central nervous system microglia, immune 
cell sentinels that can sequester Aβ [4, 9, 14-16], may 
offer great promise for new therapies.  Furthermore, 
identification of microglial cytoprotective pathways for 
entities such as EPO and Wnt1 [59-61] may 
synergistically enhance the development of treatments 
for Alzheimer’s disease. 
 
We show that EPO protects microglia against Aβ 
exposure during both early and late phases of apoptotic 
cell injury similar to prior studies with other injury 
models in non-neuronal cells [33, 34, 62].  During early 
apoptotic injury, externalization of membrane PS 
residues lead to the phagocytic removal of functional 
cells such as erythrocytes during anemia [63], neurons 
during oxidative stress [3, 64], and vascular cells during 
metabolic disorders and hypercoagulable states [51, 65].  
As a result, EPO blocks early apoptotic signaling in 
microglia and may assist with tissue repair, 
regeneration, or the removal of cancer cells by 
maintaining the presence of functional microglia [16, 
33, 66].  EPO maintains microglia during Aβ exposure 
through Wnt1 consistent with prior studies with 
wingless signaling pathways [20, 34, 45], since gene 
reduction of Wnt1 prevents the onset of early and late 
apoptotic injury in microglia by EPO.  However, we 
now illustrate that Wnt1 employs pathways that extend 
beyond traditional canonical and non-canonical Wnt 
signaling [36, 67-70].  We demonstrate that EPO 
through Wnt1 controls PI 3-K/Akt1 signaling to 
promote microglial survival during Aβ exposure, 
consistent with the known cytoprotective role for PI 3-K 
and Akt1.  Wnt1 has previously been shown to activate 
the PI 3-K/Akt1 pathway during serum deprivation, 
ischemic injury, experimental diabetes [4, 20, 41, 43, 
48] as well as tumor growth [71, 72].  Akt can foster 
cell growth and survival during inflammation, 
cardiovascular disease, and neurodegeneration [20, 21, 
37, 50, 73, 74].   
 
Once Akt1 becomes active through PI 3-K signaling, 
mTOR and p70S6K are also phosphorylated and 
activated [53, 75].  Wnt1 has been shown to require 
mTOR activation during breast cancer cell proliferation 
[76], to drive hair follicle proliferation and stem cell 
modulation [77], and to promote inflammatory cell 
survival during oxidant stress [34].  We now show that 
microglial survival during Aβ toxicity is dependent 
upon the activation of mTOR and p70S6K through both 
EPO and Wnt1 following PI 3-K and Akt1 activation.  
Combined treatment with EPO and Wnt1 did not 
provide a synergistic increase in the levels of 
phosphorylation of mTOR and p70S6K, but inhibition 
of the PI 3-K/Akt1 pathway prevented EPO and Wnt1 
from activating mTOR and p70S6K, suggesting that 
Wnt1 may be the common pathway for EPO activation 
of mTOR and p70S6K.   
 
EPO can block apoptotic injury through the 
maintenance of mitochondrial membrane potential and 
the inhibition of caspase activity during cardiovascular 
injury, renal disease, metabolic injury, and 
neurodegeneration [20, 22, 23, 28, 78-80].  Wnt 
signaling also has been shown to modulate 
mitochondrial and caspase apoptotic pathways in a 
number of cell types [4, 43, 71].  Common to both EPO 
and Wnt1 through our present work, PI 3-K and Akt1 
also can oversee mitochondrial membrane permeability 
and caspase activation [49-51].  We now demonstrate in 
a series of studies that Wnt1 maintains mitochondrial 
membrane permeability and blocks caspase activation 
through Bad, Bax, and Bcl-xL.  First, EPO and Wnt1 
during Aβ exposure phosphorylate Bad and promote the 
translocation of Bad from the mitochondria to the 
cytosol of microglia.  Phosphorylation of Bad is 
controlled by Wnt1 [43], but in addition we show that 
Bad phosphorylation through Wnt1 also requires the 
activation of mTOR which is necessary for microglial 
survival [75].  A pro-apoptotic Bcl-2 family member, 
Bad can be phosphorylated through Akt, bind to the 
cytosolic protein 14-3-3 to release Bcl-xL, and allow 
Bcl-xL to bind to the pro-apoptotic protein Bax [24, 81-
83].  Bcl-xL is necessary to block Bax translocation to 
the mitochondria, maintain mitochondrial membrane 
potential, and prevent the release of cytochrome c from 
the mitochondria [39, 59].  Second, we demonstrate that 
EPO and Wnt1 significantly limit the expression of the  
Bad/Bcl-xL complex during Aβ exposure and that Wnt1 
is critical to allow Bad to release Bcl-xL  to block 
   
www.impactaging.com                    196                                         AGING,  March 2012, Vol.4 No.3apoptosis.  Furthermore, we show that Wnt1 is 
necessary for EPO to promote the Bcl-xL/Bax complex 
during Aβ exposure to prevent Bax translocation to the 
mitochondria. 
 
We illustrate that EPO through Wnt1 also maintains 
microglial mitochondrial membrane permeability during 
Aβ exposure.  As a result, the activity of caspase 1 and 
caspase 3, mediators of early and late phases of the 
apoptotic cascade [47, 84-86], are also blocked through 
Wnt1.  EPO has been shown to rely upon modulation of 
Bcl-xL levels to promote cellular protection [22, 87, 88].  
In addition, Akt1 has been shown to prevent early PS 
membrane mediated apoptotic injury [22, 89] that is 
regulated through Bcl-xL expression [22, 50, 90, 91].   
We now show that EPO controls early and late 
apoptotic injury and caspase 1 and caspase 3 activities 
in microglia during Aβ exposure through Wnt1 that 
oversees Bcl-xL expression. 
 
Our studies identify novel signal transduction pathways 
of Aβ degeneration for the protection of central nervous 
system microglia.  In this respect, EPO through Wnt1 
governs early and late apoptotic Aβ microglial injury 
through non-traditional canonical and non-canonical 
pathways that involve the integration of the PI 3-K/Akt1 
pathways, mTOR, and mitochondrial related signaling 
of Bad, Bax, and Bcl-xL.  Future studies that further 
elucidate the pathways of cell toxicity for microglia 
during Aβ exposure may open new approaches for 
previously unrecognized strategies against Alzheimer’s 
disease and other degenerative disorders. 
 
MATERIALS AND METHODS 
 
Microglial cell cultures.    Per our prior protocols, the 
microglial cell line EOC 2 was obtained from American 
Type Culture Collection (ATTC, Manassas, VA.) [34, 
43].  Cells were maintained in Dulbecco’s modified 
Eagle medium (ATTC, Manassas, VA), supplemented 
with 10% heat-inactivated fetal bovine serum (Sigma, 
St Louis, MO), 50 μg/ml penicillin and streptomycin 
and 20% media from the LADMAC cell line (ATCC, 
Manassas, VA) which contains colony stimulating 
factor-1 (CSF-1) secreted by LADMAC cells.  Cells 
were seeded onto 24-well plates or 35 mm culture 
dishes at a density of 1.5 × 10
6 cells per well or 4 × 10
6 
cells per dish. 
 
Experimental treatments.  Per our prior protocols [3, 4, 
34], β-amyloid (Aβ1-42) (Invitrogen, Carlsbad, CA) was 
dissolved in PBS at a concentration of 100 μM.  To 
allow for Aβ aggregation, Aβ was incubated at 37
oC for 
a 7 day period and then directly applied to microglial 
cell cultures per the experimental protocols.  For 
treatments applied prior to Aβ, human recombinant 
erythropoietin (EPO) (10 ng/ ml, Sigma, St Louis, MO), 
human recombinant Wnt1 protein (100 ng/ml, R&D 
Systems, Minneapolis, MN), the mammalian target of 
rapamycin (mTOR) inhibitors rapamycin (RAPA, 20 
nM, Tocris, Ellisville, MO) or Ku 0063794 (KU, 100 
nM, Tocris, Ellisville, MO) were continuous.  For PI 3-
K inhibition, LY294002 (Calbiochem, La Jolla, CA) 
was added directly to the cultures 1 hour prior to Aβ 
application and the treatment of PI 3-K inhibition was 
continuous. 
 
Assessment of cell survival.   Microglial injury was 
determined by bright field microscopy using a 0.4% 
trypan blue dye exclusion method 24 hours following 
treatment with Aβ per our previous protocols [34, 43].  
The mean survival was determined by counting eight 
randomly selected non-overlapping fields with each 
containing approximately 10-20 cells (viable + non-
viable).  Each experiment was replicated 6 times 
independently with different cultures. 
 
Assessment of DNA fragmentation. Genomic DNA 
fragmentation was determined by the terminal 
deoxynucleotidyl transferase nick end labeling 
(TUNEL) assay [24, 50].  Briefly, microglial cells were 
fixed in 4% paraformaldehyde/0.2% picric acid/0.05% 
glutaraldehyde and the 3’-hydroxy ends of cut DNA 
were labeled with biotinylated dUTP using the enzyme 
terminal deoxytransferase (Promega, Madison, WI) 
followed by streptavidin-peroxidase and visualized with 
3,3’-diaminobenzidine (Vector Laboratories, Burlin-
game, CA).  
 
Assessment of membrane phosphatidylserine (PS) 
membrane externalization.   Externalization of 
membrane PS residues was determined by using 
Annexin V labeling per our prior studies [24, 50].  A 30 
μg/ml stock solution of Annexin V conjugated to 
phycoerythrin (PE) (R&D Systems, Minneapolis, MN) 
was diluted to 3 μg/ml in warmed calcium containing 
binding buffer (10 mmol/L Hepes, pH 7.5, 150 mmol/L 
NaCl, 5 mmol/L KCl, 1 mmol/L MgCl2, 1.8 mmol/L 
CaCl2).  Plates were incubated with 500 μl of diluted 
Annexin V for 10 minutes.  Images were acquired with 
"blinded" assessment with a Leitz DMIRB microscope 
(Leica, McHenry, IL) and a Fuji/Nikon Super CCD (6.1 
megapixels) using transmitted light and fluorescent 
single excitation light at 490 nm and detected emission 
at 585 nm.  
 
Gene reduction of Wnt1 and Bcl-xL with siRNA 
transfection.  Microglia were plated into 35  mm 
dishes or 24 well plates.  To silence Wnt1 gene 
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mouse Wnt1 mRNA.  This siRNA consists of a RNA 
duplex containing a sense strand 5’-
GCAGUACAACAUCGAUUUtt-3’ and an antisense 
strand 5’-AAAUCGAUGUUGUCACUGCag-3’.  The 
siRNA was designed by using Silencer® siRNA 
construction kit synthesized by Ambion (Austin, TX).  
To silence Bcl-xL gene expression, commercial reagents 
using the SMARTpool siRNA pool for Bcl-xL (Santa 
Crutz, Santa Crutz, CA) were used.  Transfection of 
siRNA duplexes were performed with Lipofectamine 
2000 reagent according to manufacturer guidelines 
(Invitrogen, Carlsbad, CA).  Experimental assays were 
performed 72 hours post-transfection.  For each siRNA 
assay, negative controls contain multiple siRNAs 
including the target siRNA and positive controls are 
absent of the target siRNA.   
 
Expression of phosphorylated Akt1, total Akt1, 
phosphorylated mTOR, total mTOR, phosphorylated 
p70S6K, total p70S6K, Wnt1, Bad, Bcl-xL, and Bax. 
Cells were homogenized and each sample (50 µg/lane) 
was subjected to SDS-polyacrylamide gel electrophoresis 
(7.5% for Akt, mTOR, p70S6K; 12.5% for Wnt1, Bad, 
Bcl-xL, and Bax).  After transfer, the membranes were 
incubated with a rabbit polyclonal antibody against Wnt1 
(1:1000, R&D Systems, Minneapolis, MN), a rabbit 
monoclonal antibody against phospho-Akt1 (Ser
473, 
1:1000) and total Akt1 (1:1000) (Cell Signaling, Beverly, 
MA), a rabbit monoclonal antibody against phospho-
mTOR (Ser
2448, 1:1000) and total mTOR (Cell Signaling, 
Beverly, MA), a rabbit antibody against phopho-p70S6K 
(Thr
389, 1:1000) and total p70S6K (1:1000) (Cell 
signaling Technology, Beverly, MA), a primary rabbit 
against phospho-Bad (Ser
136, 1:1000) (Cell signaling 
Technology, Beverly, MA), a primary rabbit against 
phospho- Bcl-xL (1:1000) (Cell signaling Technology, 
Beverly, MA), or a primary rabbit against phospho- Bax 
(1:1000) (Cell signaling Technology, Beverly, MA).   
Following washing, the membranes were incubated with 
a horseradish peroxidase (HRP) conjugated secondary 
antibody goat anti-rabbit IgG (1:5000, Zymed Labora-
tories, Carlsbad, CA).  The antibody-reactive bands were 
revealed by chemiluminescence (Amersham Pharmacia 
Biotech, Piscataway, NJ) and band density was 
performed using the public domain NIH Image program 
(developed at the U.S. National Institutes of Health and 
available at http://rsb.info.nih.gov/nih-image/). 
 
Akt kinase activity assessment. Per our prior work [4, 
50], Akt1 activity was determined by using a 
commercially available nonradioactive Akt1 kinase 
assay kit with a GSK-3β fusion protein.  Cells were 
lysed in ice with 150 μl of lysis buffer containing 1% 
Triton X-100, 10% glycerol, 137  mM NaCl, 20 mM 
Tris-HCl (pH 7.5), 2 μg/ml aprotinin, 2 μg/ml 
leupeptin, 1 mM phenylmethylsulfonyl fluoride, 20 mM 
NaF, 1 mM Na2PPi, and 1 mM Na3VO4.  Equal 
amounts of lysates (200 μg) were pre-cleared by 
centrifugation and pre-absorbed with protein A-protein 
G (1:1) agarose slurry.  Immunoprecipitation was 
carried out over night using the immobilized anti-
Akt1G1 monoclonal antibody (Cell Signaling 
Technology, Beverly, MA) cross-linked to agarose.   
Immunoprecipitates were washed three times with lysis 
buffer and twice with Akt kinase buffer (20  mM 
HEPES, pH 7.4, 10 mM MgCl2, 10 mM MnCl2).  
Kinase assays were performed for 30 min at 30°C under 
continuous agitation in kinase buffer containing 200 μM 
ATP and 1 μg of GSK-3 fusion protein according to the 
manufacturer's instructions (Cell Signaling Technology, 
Beverly, MA).  Samples were analyzed by Western blot 
analysis using 12.5% SDS-polyacrylamide gel and 
rabbit antibody against p-GSK-3α/β (Cell Signaling 
Technology, Beverly, MA).  Data for the kinase activity 
were expressed as percentage of control activity. 
 
Assessment of mitochondrial membrane potential.  The 
fluorescent probe JC-1 (Molecular Probes, Eugene, 
OR), a cationic membrane potential indicator, was used 
to assess the mitochondrial membrane potential [21, 
50].  Microglia in 35 mm dishes were incubated with 2 
μg/ml JC-1 in growth medium at 37 °C for 30 min.  The 
cultures were washed three times using fresh growth 
medium.  Mitochondria were then analyzed 
immediately under a Leitz DMIRB microscope (Leica, 
McHenry, IL, USA) with a dual emission fluorescence 
filter with 515-545 nm for green fluorescence and 
emission at 585-615 nm for red fluorescence. 
 
Immunoprecipitation of Bad, Bcl-xL or Bax. Cell lysates 
of total protein (200 μg) were incubated with antibody 
against protein Bad (1:1000, Cell Signaling, Beverly, 
MA) or Bcl-xL (1:1000, Cell Signaling, Beverly, MA) 
overnight at 4°C.  The complexes were collected with 
protein A/G-agarose beads, centrifuged and then 
prepared for Bad, Bax, and Bcl-xL western analysis. 
 
Statistical analysis. For each experiment, the mean and 
standard error were determined.  Statistical differences 
between groups were assessed by means of analysis of 
variance (ANOVA) from 6 replicate experiments with 
the post-hoc Dunnett's test.  Statistical significance was 
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